Biotech Calendar: Key Dates for November

BOSTON (TheStreet) -- A calendar of important, potentially stock-moving biotech events for November:

Oct. 30-Nov. 4
The American Association for the Study of Liver Disease convenes in Boston. This is the most important meeting for hepatitis C drug research held on the U.S. every year. Stocks to watch include Vertex Pharmaceuticals(VRTX), InterMune(ITMN), Pharmasset(VRUS), Schering-Plough(SGP) and Merck(MRK)

Nov. 2
Results from the "Bliss-76" phase III study of Human Genome Sciences'(HGSI) lupus drug Benlysta.

Nov. 3-4
Oppenheimer & Co. Healthcare conference

Nov. 9
FDA approval decision date for Xenoport's(XNPT) XP-13512 in restless leg syndrome. (With GlaxoSmithKline(GSK) as marketing partner.)

Nov. 10
Cephalon(CEPH) R&D Day

Nov. 10-14
Chemotherapy Foundation Meeting

Nov. 13
FDA approval decision date for Cadence Pharmaceuticals'(CADX) Acetavance (IV acetaminophen for hospital use)

Nov. 14-15
FDA approval decision date for Genzyme's(GENZ) Lumizyme for Pompe disease

Nov. 14-18
American Heart Association Scientific Sessions

Nov. 15-19
AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference

Nov. 16
FDA approval decision date for NeurogesX's(NGSX) Qutenza for neuropathic pain

Nov. 17-18
Lazard Capital Management Healthcare Conference

Nov. 20
FDA approval decision date for Human Genome Science's Abthrax for anthrax infection

Important clinical trials with potential data readouts or other biotech events expected in November:

Dendreon(DNDN) resubmission of Provenge to FDA
Expected mid-November

FDA approval decision date for Auxillium Pharmaceuticals'(AUXL) Xiaflex for Dupuytren's Contracture. (With Pfizer(PFE) as marketing partner.)
Expected mid-November

Company: Alkermes(ALKS)
Drug/indication: Vivitrol for opioid dependence
Clinical trial event: Phase III top-line results
Timing: Fourth quarter 2009

Company:Chelsea Therapeutics(CHTP)
Drug/indication: Droxidopa for orthostatic hypotension
Timing: Fourth quarter 2009

Company:Gilead Sciences(GILD)
Drug/indication: Darusentan for resistant hypertension
Timing: Fourth quarter 2009